ArticleLeukemia2016

Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.

A E Teo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.